NASDAQ: GPCR - Structure Therapeutics Inc.

Altı ay boyunca karlılık: -47.38%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Structure Therapeutics Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

daha fazla ayrıntı
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 20.4
Günlük fiyat değişimi: +3.19% (20.4)
Haftalık fiyat değişimi: -6.94% (22.62)
Aylık fiyat değişimi: -13.48% (24.33)
3 ayda fiyat değişimi: -32.64% (31.25)
Altı ayda fiyat değişimi: -47.38% (40)
Yıllık fiyat değişimi: -40.54% (35.4)
3 yılda fiyat değişimi: 0% (21.05)
5 yılda fiyat değişimi: 0% (21.05)
10 yılda fiyat değişimi: 0% (21.05)
Yılbaşından bu yana fiyat değişimi: -24.55% (27.9)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
Toplam: 2.75

Yeterlik

İsim Anlam Seviye
ROA, % -18.58 0
ROE, % -19.77 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0536 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 640268.75 10
karlılık EPS, % 31968.75 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416
0.24522.420.84



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 yıl)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 yıl)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 yıllar)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 yıl)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

Adres: United States, South San Francisco. CA, 611 Gateway Boulevard - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://structuretx.com